Olema Oncology
Brandon Robello is a Senior Research Associate at Olema Oncology, with experience in designing and optimizing automated scripts for high-throughput screening assays and visualizing large datasets using scientific computing tools. Prior roles include Research Associate II and Research Associate in In Vitro Pharmacology at Atreca, Inc., where Brandon performed flow cytometry experiments and collaborated on therapeutic candidate characterization. Additionally, experience includes medical assistant roles at LA Spine Ortho Group and ScribeAmerica, along with positions at Kite Pharma as a Cell Therapy Specialist and as a Research Assistant. Brandon holds a Bachelor of Science in Biology from Loyola Marymount University and is currently pursuing a Master of Science in Molecular Science and Software Engineering at the University of California, Berkeley.
Olema Oncology
Olema Oncology is a biopharmaceutical company developing innovative targeted therapies for women’s cancers. Their lead program, OP-1250, a potential best-in-class complete estrogen receptor antagonist (CERAN), is in development to treat estrogen receptor-positive (ER+), human epidermal growth factor receptor 2-negative (HER2-) breast cancer. Olema recently initiated a Phase 1/2 dose-escalation and expansion clinical trial of OP-1250. They are supported in their mission by experienced and accomplished scientists and board members, leading healthcare investors and some of the most innovative pharma companies.